Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $23

Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $23.
byBenzinga Newsdesk
February 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $23.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Liquidia Corporation Announces $100M In New Financings; Agreed To $75M Sale Of Common Stock To Fund Affiliated With Patient Square Capital In A Private Placement; Additional Advance Of $25M From Healthcare Royalty Under Current Financing Agreement

By Benzinga Newsdesk
January 4, 10:15 AM
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing

LQDA